Karolinska Development AB

Karolinska Development divests its holding in Pharmanest to an investment consortium comprising Östersjöstiftelsen, Recipharm Venture Fund and Praktikerinvest

Karolinska Development implements a more prudent and representative approach to reporting the fair value of its portfolio – divestment of Pharmanest

Karolinska Development´s Annual General Meeting 2015

Karolinska Development AB (publ) – Interim Report January – March 2015

Karolinska Development – Interim Report January – March, invitation to conference call and webcast

Karolinska Development’s Annual Report 2014 has been published

Karolinska Development announces preliminary portfolio valuation for the January-March 2015 Interim Report

Aprea presents preliminary clinical Phase Ib/II results in ovarian cancer at AACR with APR-246 – a novel candidate drug that restores mutant p53 protein into its wild-type function

Notice of Annual General Meeting in Karolinska Development AB (publ)

Clanotech granted Orphan Drug Designation by the U.S. FDA

Karolinska Development sells its stake in Axelar to Östersjöstiftelsen

Dilaforette receives Orphan Drug Designation in the U.S. for sevuparin in Sickle-Cell Disease

Jim Van heusden appointed CEO of Karolinska Development

Karolinska Development confirms full payment in the rights issue of convertibles

Dilaforette Announces Co-Development Agreement with Ergomed for Sickle-Cell Disease Treatment

Karolinska Development AB (publ) – Year-End Report 2014

CEO Bruno Lucidi leaves Karolinska Development and Deputy CEO Terje Kalland is appointed Acting CEO

Update of Karolinska Development rights issue outcome

Karolinska Development announces outcome of the rights issue of convertibles

Change of number of shares and votes in Karolinska Development

Purchase of own shares to cover social security fees related to incentive program

Karolinska Development’s Extraordinary General Meeting

The option rights with Athera will not be exercised due to re-evaluation of Boehringer Ingelheim’s R&D strategy – clinical development of Athera’s antibody proceeds as planned

Extraordinary General Meeting in Karolinska Development AB (publ)

Karolinska Development secures funding from CP Group, a leading Asian life science investor, and initiates preparation for a convertible bond issue

Karolinska Development AB (publ) – Interim Report January – September 2014

Athera initiates Phase I trial with its fully human antibody PC-mAb

Clanotech receives orphan drug designation in the EU

OssDsign’s Cranioplug receives marketing approval in the US

Forendo Pharma announces the US licensing of fispemifene to Apricus Biosciences targeting urological conditions in men